Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL193720 | 0.90 | GRM5 (0.53) | ALDH1A1LMNAMAPTHDAC4SMN1; SMN2 | |
| SCHEMBL194148 | 0.90 | GRM5 (0.53) | ALDH1A1LMNAMAPTHDAC4SMN1; SMN2 | |
| SCHEMBL4423384 | 0.87 | GPR119 (0.59) | GPR119ALDH1A1LMNAHDAC4SMN1; SMN2 | |
| SCHEMBL4414448 | 0.86 | GPR119 (0.56) | GPR119ALDH1A1LMNAHDAC4SMN1; SMN2 | |
| SCHEMBL4414338 | 0.86 | GPR119 (0.56) | GPR119ALDH1A1LMNAHDAC4SMN1; SMN2 | |
| SCHEMBL12580564 | 0.86 | HDAC4 (0.56) | GPR119ALDH1A1LMNAHDAC4SMN1; SMN2 | |
| SCHEMBL4419288 | 0.86 | LMNA (0.59) | GPR119LMNAMAPTHDAC4SMN1; SMN2 | |
| SCHEMBL2901393 | 0.86 | TUBB4A (0.58) | GPR119LMNAHDAC4SMN1; SMN2TSHR | |
| SCHEMBL31260537 | 0.86 | HDAC4 (0.56) | GPR119ALDH1A1LMNAHDAC4SMN1; SMN2 | |
| SCHEMBL4420449 | 0.86 | LMNA (0.61) | GPR119ALDH1A1LMNAMAPTHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885ALDH1A1 1059/4885LMNA 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.